Method of producing highly watersoluble cyclodextrin complex

Abstract: The present invention provides 1) a method of producing a complex of a fumagillol derivative of the formula: wherein R¹ is hydrogen; R² is halogen, N(O)mR⁵R⁶, N + R⁵R⁶R⁷.X- or S(O)nR⁵, wherein R⁵, R⁶ and R⁷ are independently an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X- is a counter anion; m is 0 or 1; n is an integer of 0 to 2; and R⁵ and R⁶ together with the adjacent nitrogen or sulfur atom may form an optionally substituted nitrogen- or sulfur-containing heterocyclic group which may form a condensed ring; or R¹ and R² are combined to represent a chemical bond; R³ is 2-methyl-1-propenyl group or isobutyl group; A is oxygen or NR⁸, wherein R⁸ is hydrogen or an optionally substituted lower alkyl or aryl group; and R⁴ is hydrogen, an optionally substituted hydrocarbon group or an optionally substituted acyl group; or a physiologically acceptable salt thereof, with a highly water-soluble cyclodextrin derivative, which comprises mixing the fumagillol derivative or a physiologically acceptable salt thereof with the highly water-soluble cyclodextrin derivative into an aqueous solution, the concentration of the highly water-soluble cyclodextrin derivative being at about 100 mg/ml or more, and 2) the complex of the fumaggillol derivative (I) or physiologically acceptable salt thereof with the highly water-soluble cyclodextrin derivative obtained by the production method 1). The complex of the fumagillol derivative (I) or physiologically acceptable salt thereof with the highly water-soluble cyclodextrin derivative is highly soluble in water, highly stable in storage and can be used as a preparation for injection.

Description: The present invention relates to a method of producing a complex of 6-O-(N-chloracetylcarbamoyl)fumagillol (or a salt thereof) which inhibits angiogenesis and has therapeutic and prophylactic effects on various inflammatory diseases (e.g., arthrorheumatis), diabetic retinopathy and tumors (e.g., cancer such as mastocarcinoma, hepatoma, large intestinal cancer and kaposi's sarcoma) with a highly water-soluble cyclodextrin wherein the water solubility of said fumagillol derivative is enhanced, in order to promote its absorption and heighten its pharmacological activity. Background of the Invention Conventional methods of forming a cyclodextrin complex or inclusion compound of a drug slightly soluble in water include the method in which a saturated aqueous solution of the drug and cyclodextrin is cooled to precipitate the complex, the method in which an aqueous solution of the drug and cyclodextrin is lyophilized [M. Kurozumi et al., Chemical and Pharmaceutical Bulletin, 23, 1421 (1975)], and the mixed milling method [Y. Nakai et al., Chemical and Pharmaceutical Bulletin, 26, 2419 (1978)]. However, the solubility of the complex of a slightly water-soluble drug and cyclodextrin as obtained by these methods is not sufficient to permit its use as an injection. Also, drug stability is lessened in some cases. Further, Japanese published unexamined patent application No. 63135402 mentions the pharmaceutical composition which comprises maltosyl-β-cyclodextrin and at least one compound selected from the group consisting of digitonin, nifedipine, flurubiprofen, isosorbide-nitrate, phenytoin, progesterone and testosterone. However, the reference is silent about a fumagillol derivative. EP-A-0 461 427 A2 discloses complexes of a fumagillol derivative with an optionally etherified cyclodextrin derivative. EP-A-0 335 545 A2 discloses complexes of cyclodextrin with drugs which are purely soluble and/or unstable in water, however, fumagillol derivatives are not disclosed. EP-A-0 447 351 A1 discloses a complex of O-chloracetyl-carbamoylfumagillol with cyclodextrin sulfates. EP-A-0 519 428 A2, which is only relevant under Article 54(3) EPC discloses a process for the preparation of a complex of a fumagillol derivative with a cyclodextrin which comprises mixing a solution of a fumagillol derivative in a water-soluble organic solvent with cyclodextrin and water. EP-A-0 325 199 A2 discloses complexes of fumagilin with sulfate cyclodextrins. There is demand for the development of a complex usable as a preparation for injection and of a method of industrial production thereof by increasing the solubility and stability of the fumagillol derivative, a drug which is only slightly soluble in water. In view of this situation, the present inventors investigated increasing the water solubility of a fumagillol derivative (or a salt thereof), which is slightly soluble in water, and found that a liquid complex with markedly improved solubility of a fumagillol derivative can be obtained by suspending the fumagillol derivative in an aqueous solution containing highly water-soluble cyclodextrin derivative at about 100 mg/ml or more, stirring the suspension to obtain a solution, and filtering the solution to remove the undissolved fumagillol derivative upon completion of the progress of dissolution, and that a powdered complex with markedly improved water solubility of the fumagillol derivative can be obtained by drying the liquid. The inventors made further investigations based on this finding, and developed the present invention. Summary of the Invention The present invention relates to: a method of producing a complex of 6-O-(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof, with a highly water-soluble cyclodextrin derivative selected from the group consisting of glucosyl-α-, -β-, -γ-, or -δ-cyclodextrin, maltosyl-α-, β-, γ-, or δ-cyclodextrin, maltotriosyl-α-, β-, γ-, or -δ-cyclodextrin, and dimaltosyl-α-, -β-, -γ-, or -δ-cyclodextrin, which comprises mixing 6-O-(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof with the highly water-soluble cyclodextrin derivative in an aqueous solution, the concentration of the highly water-soluble cyclodextrin derivative being at 100 mg/ml or more; and a complex of 6-O(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof, with a highly water soluble cyclodextrin derivative selected from the group consisting of glucosyl -α-, -β-, -γ-, or -δ-cyclodextrin, maltosyl-α-, -β-, -γ-, or -δ-cyclodextrin, maltotriosyl-α-, -β-, -γ-, or -δ-cyclodextrin, and dimaltosyl-α-, -β-, -γ-, or -δ-cyclodextrin, which is produced by mixing 6-O-(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof with the highly water-soluble cyclodextrin derivative in an aqueous solution, the concentration of the highly water-soluble cyclodextrin derivative being at 100 mg/ml or more. The fumagillol derivative may be used as a physiologically acceptable salt. Such physiologically acceptable salts include salts with an inorganic base, salts with an organic base, salts with an inorganic acid, salts with an organic acid and salts with basic or acidic amino acids. Inorganic bases capable of forming such salts include alkali metals (e.g., sodium, potassium) and alkaline earth metals (e.g., calcium, magnesium). Organic bases capable of forming such salts include trimethylamine, triethylamine, pyridine, picoline, N,N-dibenzylethylenediamine, ethanolamine, diethanolamine, trishydroxymethylaminomethane and dicyclohexylamine. Inorganic acids capable of forming such salts include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid. Organic acids capable of forming such salts include formic acid, acetic acid, trifluoroacetic acid, oxalic acid, tartaric acid, fumaric acid, maleic acid, methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid. Basic or acidic amino acids capable of forming such salts include arginine, lysine, ornithine, aspartic acid and glutamic acid. Of these salts, those with a base (i.e., salts with an inorganic base, salts with an organic base, salts with a basic amino acid) are salts which can be formed with the carboxyl group among the substituents for fumagillol derivative (I), and those with an acid (i.e., salts with an inorganic acid, salts with an organic acid, salts with an acidic amino acid) are salts which can be formed with, for example, the amino group, lower alkylamino group, di- lower alkylamino group or nitrogen-containing heterocyclic group among the substituents for the fumagillol derivative. The fumagillol derivative or a salt thereof can be produced by using fumagillol, the hydrolyzate of microbially produced fumagillin [Tarbell, D.S. et al., Journal of American Chemical Society, 83 , 3096 (1961)] as the starting material. Methods of its production and its physical, chemical and biological properties are described in detail in EP-A-359,036, EP-A-357,061, EP-A-354,787, EP-A-386,667, EP-A-415,294 and other publications. The highly water-soluble cyclodextrin derivative (hereinafter also referred to as CyD) is 100 mg/ml or more, preferably 130 mg/ml or more in water solubility. The highly water-soluble cyclodextrin derivatives are selected from glucosyl-α-, -β-,-γ- and -δ-CyD, maltosyl-α-, -β-, -γ- and -δ-CyD, maltotriosyl-α-, -β-, -γ- and -δ-CyD and dimaltosyl-α-, -β-, -γ- and. -δ-CyD. Among these, glucosyl-α-, -β-, -γand -δ-CyD and maltosyl-α-, -β-, -γ- and -δ-CyD are more preferable. Glucosyl-β-CyD and maltosyl-β-CyD are most preferable. These highly water-soluble cyclodextrin derivatives may be used singly or in combination of two or more kinds. The amount of highly water-soluble cyclodextrin derivative to be used is preferably 1 to 5 mols, more preferably 1.5 to 3 mols per mol of the fumagillol derivative (I) or salt thereof. Concerning the form of the complex of the present invention, the fumagillol derivative or salt thereof is more stable in a solid state, and it is preferable to prepare the complex as a powder by distilling off the water which is present by itself. Methods of distillation include lyophilization and drying under reduced pressure and, as the case may be, evaporation under normal pressure. For stabilization of the fumagillol derivative or salt thereof, lyophilization or freezing followed by drying under reduced pressure is appropriate. For producing the complex of the present invention, the fumagillol derivative (or a salt thereof) and the highly water-soluble cyclodextrin derivative are made into the state of solution in water or buffer normally at room temperature (-5 to 35°C). Said solution can be obtained by: for example, a) mixing a water or buffer solution of the highly water-soluble cyclodextrin derivative with the fumagillol derivative (or a salt thereof); b) mixing a water or buffer solution of the highly water-soluble cyclodextrin derivative with a water or buffer suspension of the fumagillol derivative (or a salt thereof); c) mixing the highly water-soluble cyclodextrin derivative and the fumagillol derivative (or a salt thereof) with water or buffer; d) mixing the highly water-soluble cyclodextrin deivative with a water and buffer suspension of the fumagillol derivative (or a salt thereof). The solutions or suspensions may be cooled or warmed if necessary. The concentration of highly water-soluble cyclodextrin derivative is preferably 100 mg/ml or more, more preferably 130 mg/ml or more. It is preferable to add the fumagillol derivative (I) or salt thereof to the aqueous solution of the highly water-soluble cyclodextrin derivative so that the amount of the highly water-soluble cyclodextrin derivative in the aqueous solution will be 1 to 5 mols, preferably 1.5 to 3 mols per mol of the fumagillol derivative or salt thereof, as stated above. When the suspension of the fumagillol derivative or salt thereof is stirred, the fumagillol derivative or salt thereof dissolves gradually. It is preferable to continue stirring for over 1 minute and stop stirring upon completion of the progress of dissolution. If any portion remains undissolved, the solution is filtered to yield a complex containing the fumagillol derivative with improved solubility. For powdering said complex, the solution obtained is lyophilized or dried under reduced pressure or normal pressure. After the fumagillol derivative or salt thereof is added, if necessary, an alkaline substance can be added to the resulting suspension or solution so as to stabilize the fumagillol derivative or salt thereof. Examples of the alkaline substance include inorganic salts such as alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide, etc.), alkali metal hydrogen carbonates (e.g., sodium hydrogen carbonate, and potassium hydrogen carbonate,.), alkali metal carbonates (e.g., sodium carbonate and potassium carbonate, ), alkali metal phosphate derivatives (e.g., sodium phosphate, tribasic; sodium phosphate, dibasic; potassium phosphate, tribasic; potassium phosphate and dibasic); organic basic substances such as alkali metal salts of organic mono carboxylic acids (e.g., sodium acetate and potassium acetate ). The amount of the alkaline substance to be used is preferably about 0.0002 to 0.2 mols per mol of the fumagillol derivative or salt thereof. Most preferably, the amount of the alkaline substance to be used is 0.001 to 0.035 mols per mol of the fumagillol derivative or salt thereof. The alkaline substance can be used as it is, or alternatively, used as an aqueous solution thereof at appropriate concentration. The powder obtained through the above procedure is an inclusion compound or a complex based on static, hydrophobic interaction or hydrogen bond. Also, the powder may contain the fumagillol derivative or salt thereof and/or the highly water-soluble cyclodextrin derivative in addition to the inclusion compound or complex. Such powder is also included in the scope of the complex of the present invention. The complex of the present invention can be used as a parenteral preparation. The parenteral preparation can be produced as follows. To improve various properties (e.g., vial packing quality, specific volume, antistatic property) of the powder obtained, sugars (e.g., glucose, mannitol and inositol ), preservatives (e.g., methyl-paraben, propyl-paraben, benzyl alcohol and chlorobutanol), isotonizing agent (e.g., sodium chloride), glycerin, sorbitol, and glucose), antistatic agents (e.g., magnesium stealate, for use in injection may be added. The powder thus obtained is easily soluble in distilled water for injection and in aqueous solutions prepared with sodium chloride and, sugars (e.g., glucose, mannitol, inositol) or a dispersing agent (e.g., Tween 80 (Atlas Powder, U.S.A.), HCO-60 (Nikko Chemicals), carboxymethyl cellulose and sodium alginate ). After dissolution, a fumagillol derivative (I) or a salt thereof at a concentration effective against the target disease, in the form of a preparation for injection, can be administered intravenously, intramuscularly, subcutaneously, intraviscerally (e.g., hepatic artery) or into tumors and other lesions. Also, the powder obtained according to the present invention can be prepared in non-injection dose forms such as topical preparations (e.g., nasal preparation, dermatological preparation) and suppositories (e.g., rectal, vaginal) for use in the field of pharmaceutics. A topical preparation from the powder obtained according to this invention may be provided in a solid, semi-solid or liquid state in the conventional manner. To manufacture the solid topical preparation for instance, the powder itself or together with an excipient (e.g., glucose, mannitol, starch and microcrystalline cellulose, ) and/or thickener (e.g., natural mucilages, cellulose derivatives and polyacrylates. ) are processed into a powdery composition. To make a liquid composition, the powders obtained according to the present invention are processed into an oily or aqueous solution in substantially the same manner as in the case of injections. The semi-solid preparation may be an aqueous or oily gel or ointment. In any case, there may be added a pH adjusting agent (e.g., carbonic acid, phosphoric acid, citric acid, hydrochloric acid, sodium and hydroxide ), a preservative (e.g., p-hydroxybenzoic acid esters, chlorobutanol and benzalkonium chloride. A suppository of the powder obtained according to this invention, whether in oily or aqueous solid or semi-solid state or in liquid state, may be produced in the per se conventional manner. As examples of the kind of oleagenous base for such a composition, higher fatty acid glycerides [e.g., cacao butter, Witepsol (Dynamit-Novel, Germany) ], intermediate fatty acids [e.g., Miglyol (Dynamit-Novel) ,] and vegetable oils (e.g., sesame oil, soybean oil and cottonseed oil) may be mentioned. The aqueous base is exemplified by polyethylene glycol and propylene glycol, while the aqueous gel base may be selected from among natural mucilages, cellulose derivatives, vinyl polymers and polyacrylates. The complex of the present invention inhibits angiogenesis, and exhibits potent pharmacological action such as therapeutic and prophylactic effects on various inflamatory diseases (e.g., arthrorheumatis), diabetic retinopathy and tumors (e.g. cancer such as mastocarcinoma, hepatoma, large intestinal cancer and Kaposi's sarcoma), with low toxicity. It is useful as a drug for mammals (e.g., monkeys, bovines, dogs, humans) to prevent or treat diseases such as various inflammatory diseases (e.g., arthrorheumatis), diabetic retinopathy and tumors (e.g., cancer such as mastocarcinoma, hepatoma, large intestinal cancer and Kaposi's sarcoma). When administering the complex of the present invention by injection for the purpose of treating an adult patient having a tumor (body weight of 50 kg), for instance, the amount per dose, which varies depending on the type, activity and other factors of the fumagillol derivative or salt thereof, can be selected from the range of 1.0 mg to 5.0 g, preferably 25 mg to 2.0 g, more preferably 50 mg to 1.0 g daily. [Examples] The present invention is hereinafter described in more detail by means of the following comparative examples and working examples. Comparative Example 1 To a 5 ml aqueous solution containing 1000 mg of maltosyl-β-cyclodextrin (hereinafter abbreviated G2βCyD) was added 250 mg of 6-O-(N-chloroacetylcarbamoyl) fumagillol (hereinafter abbreviated TNP-470), followed by stirring at 25°C for 8 hours to obtain a solution. The undissolved portion of TNP-470 was filtered out, and the filtrate was placed in a vial and lyophilized in accordance with a conventional method to yield a powder. To the entire amount of the powder thus obtained, 5 ml of water was added to yield a uniform aqueous solution. Separately, in accordance with the conventional method, 110 mg of G2βCyD was dissolved in 5 ml of water; 250 mg of TNP-470 was added to this solution, followed by stirring at 25°C for 8 hours. Then, the solution was filtered. The above uniform solution and the filtered solution were assayed for TNP-470 by high performance liquid chromatography (HPLC). Also, the saturation solubility of TNP-470 alone was determined by HPLC. The results shown in Table 1 were obtained. The solubility showed almost no improvement in the conventional method, while a marked improvement occurred in the method of the present invention. Conditions for HPLC Column ODS, YMC-Pack A-312 (Yamamura Chemical Laboratories) Mobil phase water-acetonitrile (1:1 v/v) Flow rate 1.0 ml/min. Detector Ultra violet detector (wavelength: 210nm) Comparison of Solubility The present invention 36.7 mg/ml Conventional method 6.7 TNP-470 alone 1.9 Comparative Example 2 To a 5 ml aqueous solution containing 500 mg of glucosyl-β-cyclodextrin (hereinafter abbreviated G1βCyD) was added 250 mg of TNP-470, followed by stirring at 25°C for 8 hours to obtain a solution. The resulting aqueous solution was filtered and lyophilized in accordance with the standard method to yield a powder. To the entire amount of the powder thus obtained, 5 ml of water was added to yield a uniform aqueous solution. Separately, in accordance with the conventional method, 100 mg of G1βCyD was dissolved in 5 ml of water; 250 mg of TNP-470 was added to this solution, followed by stirring at 25°C for 8 hours. Then, the solution was filtered. The above uniform solution and the filtered solution were assayed for TNP-470 by HPLC method as described in Comparative Example 1. Also, the saturation solubility of TNP-470 alone was determined by HPLC. The results shown in Table 2 were obtained. The solubility showed almost no improvement in the conventional method, while a marked improvement occurred in the method of the present invention. Comparison of Solubility The present invention 23.1 mg/ml Conventional method 6.5 TNP-470 alone 1.9 Example 1 To a 5 ml aqueous solution containing 1000 mg of maltosyl-β-cyclodextrin 1 was added 100 mg of TNP-470, followed by stirring at 25°C for 30 minutes to yield a solution. This aqueous solution was filtered, and 5 ml of the filtrate was placed in a vial and lyophilized to yield a powder. Example 2 To a 5 ml aqueous solution containing 750 mg of maltosyl-β-cyclodextrin was added 100 mg of TNP-470, followed by stirring at 25°C for 30 minutes to yield a solution. This aqueous solution was filtered, and 5 ml of the filtrate was placed in a vial and lyophilized to yield a powder. Example 3 To a 5 ml aqueous solution containing 500 mg of maltosyl-β-cyclodextrin was added 100 mg of TNP-470, followed by stirring at 25°C for 30 minutes to yield a solution. This aqueous solution was filtered, and 5 ml of the filtrate was placed in a vial and lyophilized to yield a powder. Example 4 To a 5 ml aqueous solution containing 750 mg of glucosyl-β-cyclodextrin was added 100 mg of TNP-470, followed by stirring at 25°C for 30 minutes to yield a solution. This aqueous solution was filtered, and 5 ml of the filtrate was placed in a vial and lyophilized to yield a powder. Example 5 To a 5 ml aqueous solution containing 500 mg of glucosyl-β-cyclodextrin was added 100 mg of TNP-470, followed by stirring at 25°C for 30 minutes to yield a solution. This aqueous solution was filtered, and 5 ml of the filtrate was placed in a vial and lyophilized to yield a powder. Example 6 To a 5 ml aqueous solution containing 726 mg of maltosyl-β-cyclodextrin was added 100 mg of TNP-470, followed by stirring at 25°C for 180 minutes to yield a solution. This aqueous solution was filtered, and 5 ml of the filtrate was placed in a vial and lyophilized to yield a powder. The stability of this powder and that of TNP-470 alone were compared after storage at 40°C for 1 month. TNP-470 was quantified by HPLC. The results are shown in Table 3. The powder according to the present invention was found to be very stable. Stability Percent residence The present invention 96% TNP-470 alone 68% Example 7 Maltosyl-β-cyclodextrin (719g) was dissolved in water (4950ml) in a beaker (10 liters capacity). To this solution was added TNP-470 (99g), followed by stirring at 25°C for 3 hours. Upon completion of the progress of dissolution, the resulting solution was filtered through a filter having a pore size of 0.22 µm. The filtrate was filled in 5 ml portions into vials, followed by lyophilization to give a preparation for infection. Example 8 Maltosyl-β-cyclodextrin (72.3g) was dissolved in water (400ml) in a beaker (10 liters capacity). To this solution was added TNP-470 (10g), followed by stirring at 25°C for 1.5 hours. To this was added 0.1N NaOH (0.9ml), followed by stirring at 25°C for 1.5 hours. Upon completion of the progress of dissolution, water was added to the resulting solution to make up a total of 500 ml, and the solution was then filtered through a filter having a pore size of 0.22 µm. The filtrate was subjected to lyophilization to give a preparation for infection. The stability of this preparation was studied after storage at 40°C for 1 month. TNP-470 was quantified by the same HPLC method as described in Comparative Example 1. The percent residue of TNP-470 was 97%. The preparation according to the present invention was found to be very stable. Example 9 Except that 5.4ml of 0.1N NaOH was used instead of 0.9ml of 0.1N NaOH, the procedure of Example 8 was followed to give a preparation containing TNP-470 (30mg). Example 10 Except that 0.6ml of 0.1N KOH was used instead of 0.9ml of 0.1N NaOH, the procedure of Example 8 was followed to give a preparation containing TNP-470 (30mg). The production method of the present invention is industrially feasible, and the complex obtained by the production method of the present invention is easily soluble in water, highly stable in storage and can be used as a preparation for injection.

Claims: A method of producing a complex of 6-O-(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof, with a highly water-soluble cyclodextrin derivative selected from the group consisting of glucosyl-α-, -β-, -γ-, or -δ-cyclodextrin, maltosyl-α-, β-, γ-, or δ-cyclodextrin, maltotriosyl-α-, β-, γ-, or -δ-cyclodextrin, and dimaltosyl-α-, -β-, -γ-, or -δ-cyclodextrin, which comprises mixing 6-O-(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof with the highly water-soluble cyclodextrin derivative in an aqueous solution, the concentration of the highly water-soluble cyclodextrin derivative being at 100 mg/ml or more. The method according to claim 1, wherein the highly water-soluble cyclodextrin derivative is glucosyl-β-cyclodextrin. The method according to claim 1, wherein the highly water-soluble cyclodextrin derivative is maltosyl-β-cyclodextrin. The method according to claim 1, wherein the mole ratio between the highly water-soluble cyclodextrin derivative to 6-O-(N-chloroacetyl carbamoyl)-fumagillol or a physiologically acceptable salt thereof is in the range of 1.5 to 3:1. A complex of 6-O(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof, with a highly water soluble cyclodextrin derivative selected from the group consisting of glucosyl -α-, -β-, -γ-, or -δ-cyclodextrin, maltosyl-α-, -β-, -γ-, or -δ-cyclodextrin, maltotriosyl-a-,-β-, -γ-, or -δ-cyclodextrin, and dimaltosyl-α-, -β-, -γ-, or -δ-cyclodextrin, which is produced by mixing 6-O-(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof with the highly water-soluble cyclodextrin derivative in an aqueous solution, the concentration of the highly water-soluble cyclodextrin derivative being at 100 mg/ml or more. The complex according to claim 5, wherein the highly water-soluble cyclodextrin derivative is glucosyl-β-cyclodextrin. The complex according to claim 5, wherein the highly water soluble cyclodextrin derivative is maltosyl-β-cyclodextrin. The complex according to claim 5, wherein the mole ratio between the highly water-soluble cyclodextrin to 6-O-(N-chloroacetyl carbamoyl)fumagillol or a physiologically acceptable salt thereof is 1.5 to 3:1.

Inventors: NAGAI AKIHIRO, OHMACHI YOSHIHIRO, TSUGAWA YOSHIHIRO, NAGAI, AKIHIRO, OHMACHI, YOSHIHIRO, TSUGAWA, YOSHIHIRO
Applicants: TAKEDA CHEMICAL INDUSTRIES LTD, TAKEDA CHEMICAL INDUSTRIES, LTD.
Application year: 1993
Main classification: A61K47
IPC codes: A61K47